Table 4. GPELF MDA treatments (2000–2007).
| WHO Region | GPELF Countries (2000–2007) | Individuals Treated with MDA (Millions) | Treated Individuals Infected with LF (Millions)1 | Benefit Cohort Population (Millions) |
| AMRO | Brazil, Dominican Republic, Guyana, Haiti | 2.2 | 0.2 | 0.1 |
| AFRO | Benin, Burkina Faso, Cameroon, Comoros, Ghana, Kenya, Madagascar, Mali, Niger, Nigeria, Senegal, Sierra Leone, Tanzania (incl. Zanzibar), Togo, Uganda | 51.2 | 5.1 | 2.9 |
| EMRO | Egypt, Yemen | 2.7 | 0.3 | 0.2 |
| WPRO | American Samoa, Cambodia, Cook Islands, Fed. States of Micronesia, Fiji, French Polynesia, Kiribati, Marshall Islands, Malaysia, Niue, Papua New Guinea, Philippines, Samoa, Tonga, Tuvalu, Vanuatu, Vietnam, Wallis and Futuna | 17.4 | 1.7 | 1.0 |
| SEARO | Bangladesh, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand, Timor-Leste | 494.4 | 49.4 | 27.2 |
| All Regions | 48 total countries | 567.9 | 56.8 | 31.4 |
1
Assumed that 10% of at-risk population is actually infected with LF [1].